deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT04124042

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee

Sponsor: Xalud Therapeutics, Inc.

Conditions Osteoarthritis, Knee
Interventions Placebo XT-150
Updated 16 times since 2019 Last updated: Mar 7, 2025 Started: Feb 14, 2020 Primary completion: Apr 26, 2022 Completion: Apr 26, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04124042, this PHASE2 trial focuses on Osteoarthritis, Knee and remains completed. Sponsored by Xalud Therapeutics, Inc., it has been updated 16 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jul 2020 · 5 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 16 months · monthly snapshot

Change History

16 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2022 — Feb 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Feb 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  8. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Feb 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Dec 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  11. Nov 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Xalud Therapeutics, Inc.
Data source: Xalud Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations